Related Experiment Video
Updated: Oct 11, 2025
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
779
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Yaolin Xu1, Lijie He1, Qiang Fu2
1Department of Oncology, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, Shenyang, China.
Frontiers in Oncology
|December 3, 2021
Summary
Immune checkpoint inhibitors (ICIs) show promise but face resistance due to metabolic reprogramming. Targeting tumor and immune cell metabolism, particularly glycolysis, offers a strategy to enhance ICI therapy effectiveness and overcome resistance.
Area of Science:
- Immunology
- Metabolic pathways
- Cancer therapy
Background:
- Immune checkpoint inhibitors (ICIs) like Nivolumab have improved anti-tumor therapy.
- However, limited response rates and resistance hinder their efficacy.
- Metabolic reprogramming in the tumor microenvironment (TME) is a key barrier to immunotherapy.
Purpose of the Study:
- To review metabolic reprogramming in tumor and immune cells within the TME.
- To explore the impact of metabolism on anti-tumor immunity and ICI efficacy.
- To discuss targeting metabolic pathways to overcome ICI resistance.
Main Methods:
- Literature review focusing on glycolysis, amino acid, lipid, and nucleotide metabolism.
- Analysis of mitochondrial biogenesis in the TME.
- Examination of programmed cell death (ligand) 1 [PD-(L)1] expression under metabolic reprogramming.
Main Results:
- Metabolic reprogramming significantly impacts immune cell function and tumor progression.
- Targeting key metabolic pathways, including glycolysis, can enhance ICI efficacy.
- Metabolic alterations influence PD-(L)1 expression in tumor and immune cells.
Conclusions:
- Targeting tumor and immune cell metabolism is crucial for improving ICI therapy.
- Metabolic strategies hold potential for overcoming adaptive resistance to ICIs.
- Metabolic biomarkers may predict patient response to ICI treatment.
Keywords:
PD-1amino acid metabolismglycolysisimmune checkpointslipid metabolismmitochondrial biogenesisnucleotide metabolismthe tumor microenvironmentMore Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
725
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
02:17The Tumor Microenvironment
6.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:53Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
02:07Tumor Progression
6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
02:40Cancer Stem Cells and Tumor Maintenance
5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K